Title: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Journal: Lancet (London, England)20180324
Title: Lenvatinib: first global approval.
Journal: Drugs20150401
Title: A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.
Journal: British journal of cancer20120508
Title: Novel molecular targeted therapies for refractory thyroid cancer.
Journal: Head & neck20120501
Title: Unique metabolic pathway of [(14)C]lenvatinib after oral administration to male cynomolgus monkey.
Journal: Drug metabolism and disposition: the biological fate of chemicals20120401
Title: Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20120301
Title: Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts.
Journal: International journal of cancer20110801
Title: E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.
Journal: Molecular cancer therapeutics20110701
Title: Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20110415
Title: Antiangiogenic therapies for malignant pleural mesothelioma.
Journal: Frontiers in bioscience (Landmark edition)20110101
Title: E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion.
Journal: BMC cancer20110101
Title: A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.
Journal: Journal of pharmacokinetics and pharmacodynamics20100801
Title: E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20091201
Title: Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20080901
Title: E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.
Journal: International journal of cancer20080201
Title: Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173.
Title: Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25(1):1073274818789361.
Title: 3.Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14(17),545.
Title: Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008, 122(3), 664-671.
